These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 20005104)
1. The first synthetic agonists of FFA2: Discovery and SAR of phenylacetamides as allosteric modulators. Wang Y; Jiao X; Kayser F; Liu J; Wang Z; Wanska M; Greenberg J; Weiszmann J; Ge H; Tian H; Wong S; Schwandner R; Lee T; Li Y Bioorg Med Chem Lett; 2010 Jan; 20(2):493-8. PubMed ID: 20005104 [TBL] [Abstract][Full Text] [Related]
2. Identification and functional characterization of allosteric agonists for the G protein-coupled receptor FFA2. Lee T; Schwandner R; Swaminath G; Weiszmann J; Cardozo M; Greenberg J; Jaeckel P; Ge H; Wang Y; Jiao X; Liu J; Kayser F; Tian H; Li Y Mol Pharmacol; 2008 Dec; 74(6):1599-609. PubMed ID: 18818303 [TBL] [Abstract][Full Text] [Related]
3. Agonism and allosterism: the pharmacology of the free fatty acid receptors FFA2 and FFA3. Milligan G; Stoddart LA; Smith NJ Br J Pharmacol; 2009 Sep; 158(1):146-53. PubMed ID: 19719777 [TBL] [Abstract][Full Text] [Related]
4. Defining the molecular basis for the first potent and selective orthosteric agonists of the FFA2 free fatty acid receptor. Hudson BD; Due-Hansen ME; Christiansen E; Hansen AM; Mackenzie AE; Murdoch H; Pandey SK; Ward RJ; Marquez R; Tikhonova IG; Ulven T; Milligan G J Biol Chem; 2013 Jun; 288(24):17296-312. PubMed ID: 23589301 [TBL] [Abstract][Full Text] [Related]
5. A Novel Allosteric Activator of Free Fatty Acid 2 Receptor Displays Unique Gi-functional Bias. Bolognini D; Moss CE; Nilsson K; Petersson AU; Donnelly I; Sergeev E; König GM; Kostenis E; Kurowska-Stolarska M; Miller A; Dekker N; Tobin AB; Milligan G J Biol Chem; 2016 Sep; 291(36):18915-31. PubMed ID: 27385588 [TBL] [Abstract][Full Text] [Related]
6. Mutational analysis of G-protein coupled receptor--FFA2. Swaminath G; Jaeckel P; Guo Q; Cardozo M; Weiszmann J; Lindberg R; Wang Y; Schwandner R; Li Y Biochem Biophys Res Commun; 2011 Feb; 405(1):122-7. PubMed ID: 21216233 [TBL] [Abstract][Full Text] [Related]
7. Ligands at the Free Fatty Acid Receptors 2/3 (GPR43/GPR41). Milligan G; Bolognini D; Sergeev E Handb Exp Pharmacol; 2017; 236():17-32. PubMed ID: 27757758 [TBL] [Abstract][Full Text] [Related]
8. Selective orthosteric free fatty acid receptor 2 (FFA2) agonists: identification of the structural and chemical requirements for selective activation of FFA2 versus FFA3. Schmidt J; Smith NJ; Christiansen E; Tikhonova IG; Grundmann M; Hudson BD; Ward RJ; Drewke C; Milligan G; Kostenis E; Ulven T J Biol Chem; 2011 Mar; 286(12):10628-40. PubMed ID: 21220428 [TBL] [Abstract][Full Text] [Related]
9. Characterisation of small molecule ligands 4CMTB and 2CTAP as modulators of human FFA2 receptor signalling. Schofield ZV; Croker D; Robertson AAB; Massey NL; Donovan C; Tee E; Edwards D; Woodruff TM; Halai R; Hansbro PM; Cooper MA Sci Rep; 2018 Dec; 8(1):17819. PubMed ID: 30546040 [TBL] [Abstract][Full Text] [Related]
10. Extracellular loop 2 of the free fatty acid receptor 2 mediates allosterism of a phenylacetamide ago-allosteric modulator. Smith NJ; Ward RJ; Stoddart LA; Hudson BD; Kostenis E; Ulven T; Morris JC; Tränkle C; Tikhonova IG; Adams DR; Milligan G Mol Pharmacol; 2011 Jul; 80(1):163-73. PubMed ID: 21498659 [TBL] [Abstract][Full Text] [Related]
11. Pharmacology of Free Fatty Acid Receptors and Their Allosteric Modulators. Grundmann M; Bender E; Schamberger J; Eitner F Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33578942 [TBL] [Abstract][Full Text] [Related]
12. FFA2-, but not FFA3-agonists inhibit GSIS of human pseudoislets: a comparative study with mouse islets and rat INS-1E cells. Lorza-Gil E; Kaiser G; Rexen Ulven E; König GM; Gerst F; Oquendo MB; Birkenfeld AL; Häring HU; Kostenis E; Ulven T; Ullrich S Sci Rep; 2020 Oct; 10(1):16497. PubMed ID: 33020504 [TBL] [Abstract][Full Text] [Related]
13. Short-chain fatty acid receptors involved in epithelial acetylcholine release in rat caecum. Ballout J; Akiba Y; Kaunitz JD; Diener M Eur J Pharmacol; 2021 Sep; 906():174292. PubMed ID: 34216575 [TBL] [Abstract][Full Text] [Related]
14. The Quantitative Characterization of Functional Allosteric Effects. Kenakin T Curr Protoc Pharmacol; 2017 Mar; 76():9.22.1-9.22.10. PubMed ID: 28306151 [TBL] [Abstract][Full Text] [Related]
15. N-Thiazolylamide-based free fatty-acid 2 receptor agonists: Discovery, lead optimization and demonstration of off-target effect in a diabetes model. Hoveyda HR; Fraser GL; Zoute L; Dutheuil G; Schils D; Brantis C; Lapin A; Parcq J; Guitard S; Lenoir F; Bousmaqui ME; Rorive S; Hospied S; Blanc S; Bernard J; Ooms F; McNelis JC; Olefsky JM Bioorg Med Chem; 2018 Oct; 26(18):5169-5180. PubMed ID: 30253886 [TBL] [Abstract][Full Text] [Related]
16. Chemogenetics defines receptor-mediated functions of short chain free fatty acids. Bolognini D; Barki N; Butcher AJ; Hudson BD; Sergeev E; Molloy C; Moss CE; Bradley SJ; Le Gouill C; Bouvier M; Tobin AB; Milligan G Nat Chem Biol; 2019 May; 15(5):489-498. PubMed ID: 30992568 [TBL] [Abstract][Full Text] [Related]
17. Chemically engineering ligand selectivity at the free fatty acid receptor 2 based on pharmacological variation between species orthologs. Hudson BD; Christiansen E; Tikhonova IG; Grundmann M; Kostenis E; Adams DR; Ulven T; Milligan G FASEB J; 2012 Dec; 26(12):4951-65. PubMed ID: 22919070 [TBL] [Abstract][Full Text] [Related]
18. The therapeutic potential of allosteric ligands for free fatty acid sensitive GPCRs. Hudson BD; Ulven T; Milligan G Curr Top Med Chem; 2013; 13(1):14-25. PubMed ID: 23409763 [TBL] [Abstract][Full Text] [Related]